Cathie Wood Is Loading Up on These 3 Next-Gen Tech Stocks

Most asset managers try to track the market. Through ARK Investment, Cathie Wood is trying to get ahead of the market’s best ideas by identifying disruptive innovation early, even when the underlying businesses are still volatile or misunderstood. That approach leads to concentrated positions in companies tied to long-term technological shifts rather than short-term earnings stability. ARK’s portfolio currently includes Tempus AI (NASDAQ:TEM | TEM Price Prediction), Circle Internet Group (NYSE:CRCL), and CRISPR Therapeutics (NASDAQ:CRSP), according to the fund’s disclosed portfolio holdings. These four names span ARK’s core conviction themes: AI-enabled healthcare, next-generation fintech, digital dollar infrastructure, and genomic medicine. Each position reflects a distinct thesis and carries a different risk profile for retirement-oriented investors.

Tempus AI: AI Network Effects in Healthcare

ARK’s position in Tempus AI reflects a bet on AI-driven precision medicine at an inflection point. The fund increased its position by 1,888,852 shares last quarter (+24.99%), bringing Tempus to 3.23% of the portfolio, making it one of ARK’s larger holdings. Q4 2025 revenue reached $367.21 million, an 83% year-over-year increase, while adjusted EBITDA turned positive at $12.89 million, the company’s first profitable quarter on that metric. Q4 Diagnostics was the engine for the company, with revenue hitting $266.86 million, up 121.6% year-over-year, and MRD testing volume reaching approximately 4,700 tests, up 56% quarter-over-quarter.

CEO Eric Lefkofsky framed the trajectory plainly: “As the network effects from our investments in AI continue to compound, we expect to not only drive significant growth over the next several years, but to also enhance the lives of millions of patients around the world.” Management guided 2026 revenue to approximately $1.59 billion with Adjusted EBITDA of approximately $65 million. The stock trades near $55.87, up 38.12% over the past year, though down 5.39% year-to-date entering mid-April 2026. Tempus holds one of the world’s largest multimodal clinical and molecular datasets, with connections to more than 40 million clinical patient records and over 350 petabytes of connected data, creating a durable competitive moat as AI adoption in oncology accelerates.

Circle Internet Group: Stablecoin Infrastructure

Circle represents one of ARK’s clearest bets on digital dollar infrastructure. The fund increased its position by 1,174,688 shares last quarter (+39.59%), bringing the position to 2.11% of the portfolio. Q4 2025 revenue grew 76.9% year-over-year to $770.23 million, Adjusted EBITDA skyrocketed 412% year-over-year to $167 million, and average USDC in circulation doubled year-over-year to $76.20 billion. The company received OCC conditional approval for a national trust bank charter in December 2025, a regulatory milestone that de-risks the enterprise story.

CEO Jeremy Allaire described the strategic positioning: “USDC adoption continued to expand globally as more enterprises, developers, and public institutions integrated digital dollars into real-world payments, treasury, and onchain financial workflows.” Partnerships with Visa, Intuit, and Polymarket validate institutional demand. The stock trades at $105.91, up 33.56% year-to-date, and has gained 241.65% since its June 2025 IPO. The company’s primary risk is interest-rate sensitivity, as its business model depends heavily on the yield earned on its USDC reserves. A falling-rate environment directly compresses margins.

CRISPR Therapeutics: Contrarian Conviction on Gene Editing

ARK’s position in CRISPR Therapeutics stands out as one of the more contrarian bets in the portfolio. The fund increased its stake by 735,084 shares last quarter (+7.51%), bringing the position to 3.55% of the portfolio. Q4 2025 revenue collapsed to $864,000, down 97.5% year-over-year, missing the $3.48 million consensus estimate, driven entirely by the absence of CASGEVY collaboration revenue that had contributed $35 million in Q4 2024 and a surge in collaboration expenses to $53.70 million from $10.42 million year-over-year.

The headline numbers obscure genuine commercial progress. CASGEVY generated $116 million in full-year 2025 revenue, patient initiations nearly tripled year over year, and approximately 90% of U.S. patients have reimbursed access. Pediatric regulatory submissions for ages 5 to 11 are expected in H1 2026. The broader pipeline includes CTX310, which demonstrated up to 81% LDL and 82% triglyceride reductions in Phase 1 data, addressing a market of more than 40 million U.S. patients. The company holds approximately $1.976 billion in cash and investments, providing substantial runway. The stock trades at $57.99, up 53.53% over the past year. CEO Samarth Kulkarni acknowledged the complexity: “CRISPR Therapeutics continues to make steady progress across a broad and increasingly mature pipeline… these developments reflect continued execution across the portfolio.”